ALSO NOTED: Par drops Advancis partnership; Diovan gets new indication; Pozen makes case for MT-100; and much more...

> Par Pharmaceutical has pulled out of its development partnership with Advancis, saving itself a scheduled $4.75 million payment. The news follows Advancis' announcement that it would slash its staff following the failure of Amoxicillin PULSYS in Phase III trials. Story

> The FDA has approved a new indication for Novartis' bestselling Diovan, adding its use to improve survival after a heart attack. Story

> Pozen will make its case for MT-100 to the FDA today, arguing that patients taking the drug will suffer little risk of involuntary facial movements. The agency had rejected the drug last year, concerned that its effectiveness was in doubt and that patients might be at risk of a permanent movement disorder. Report

> The Texas Vioxx trial turned emotional with testimony from a daughter who believes the drug was instrumental in her father's death. Article

> One analyst cut his rating on Amylin triggering a slip in a variety of biotech stocks this morning. Story

> Zeltia is planning significant new investments in its PharmaMar unit. Story

> Nymox is touting interim data on its Phase II trial of NX-1207 for benign prostatic hyperplasia. Release

And Finally... Wounded soldiers are bringing back a drug-resistant bacteria from Iraq. Feature

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.